

Pembrolizumab KEYNOTE-177

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-177

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
 Therapeutic Indication: First-line treatment of adults with MSI-H or dMMR mCRC  
 Experimental Arm: Pembrolizumab  
 Control Arm: ChT ((5-fluorouracil-based therapy with or without bevacizumab or cetuximab)

